← Back

Beijing Science Sun Pharmaceutical Co Ltd

Beijing Science Sun Pharmaceutical Co., Ltd. is a biopharmaceutical company founded in 1999 and headquartered in Beijing, China. It researches, develops, produces, and sells injections for cardiovascular, cerebrovascular, immunomodulation, and nervous system applications, as well as other drugs. The company also manufactures raw materials, solid oral preparations, tablets, hard capsules, powders, granules, and active pharmaceutical ingredients, and is involved in traditional Chinese medicine extraction and health products. Additionally, it engages in venture capital, equity investment through private equity funds, technology development and transfer for biological products, pharmaceuticals, diagnostic reagents, and medical devices, and research and development of human vaccines.

Price · split & dividend adjusted
News & notes moving 300485.CS
300485.CS▼

Saisheng Pharmaceutical posts net loss of 144 million yuan in 2026 interim report

Saisheng Pharmaceutical released its 2026 interim report, with net profit attributable to the parent company at negative 144 million yuan, swinging from profit to loss. Total operating revenue was 181 million yuan, down 8.17% from the same period last year. Net cash inflow from operating activities was 11.4043 million yuan, down 61.13% year on year. The company's latest asset-liability ratio was 3.90%, gross margin was 67.84%, and ROE was negative 4.47%. Diluted earnings per share were negative 0.30 yuan, down 400.00% from the same period last year.
300485.CS ▼
Jiemian·26dRead more →
300485.CS▲

Saisheng Pharmaceutical Subsidiary’s Dapagliflozin Tablets Marketing Authorization Application Accepted

The marketing authorization application for dapagliflozin tablets from Beijing Saier Biological Pharmaceutical, a subsidiary of Beijing Saisheng Pharmaceutical, has been accepted by the National Medical Products Administration. The drug, available in 5 mg and 10 mg strengths, is an SGLT-2 inhibitor that lowers blood glucose by inhibiting renal tubular glucose reabsorption. It entered the Chinese market in 2017 and is taken orally once daily. The company stated that the product has entered the registration review stage and will not have a significant impact on performance in the near term, but if approved smoothly, it will further enrich the product pipeline. It also reminded investors that there is uncertainty in drug registration approval.
300485.CS ▲
Jiemian·54dRead more →
300485.CS▲

Saisheng Pharmaceutical's Urokinase for Injection and Cefixime Tablets Included in the 2026 National Essential Medicines List

Beijing Saisheng Pharmaceutical Co., Ltd. announced that two products from the company and its subsidiaries have been newly added to the National Essential Medicines List, 2026 edition. Urokinase for injection, 100,000 units, is produced by the company, while cefixime tablets, 0.1 grams, are produced by its controlled subsidiary Beijing Saier Biological Pharmaceutical Co., Ltd. The company stated that this is not expected to have a significant impact on operations in the short term, but will positively affect future market expansion, sales growth, and long-term development.
300485.CS ▲
Jiemian·71dRead more →
© 2026 MarketDXAsset